

EXECUTIVE SUMMARY

First Quarter 2024




Main figures €Mn

Op. Revenue	EBITDA	EBIT
151.2 (-25%)	25.9 (-61%)	19.3 (-68%)
Net profit	Capex	Net debt
15.0 (-68%)	9.0 (+83%)	67.2


2024 operating revenue guidance:
Decrease by a mid-single-digit percentage vs 2023

- ✓ ROVI signs an agreement to manufacture pre-filled syringes for a global pharmaceutical company
- ✓ FDA marketing approval for Risvan® (Risperidone ISM®) in the U.S. for the treatment of schizophrenia in adults
- ✓ Marketing approval for Okedi® (Risperidone ISM®) in Canada and Australia for the treatment of schizophrenia in adults
- ✓ ROVI, Insud Pharma and Innvierte (CDTI) create TeraFront Farmatech, a company for the research and development of advanced therapies

Operating revenue €Mn



Specialty pharma business €Mn



Heparin franchise* €56.3m
37% of operating revenue

Other prescription-based pharmaceutical products

Enoxaparin sales €34.6m

Neparvis® €12.2m

- ✓ Directly marketed in Germany, UK, Italy, France, Belgium, Portugal, Spain, Poland and Austria.
- ✓ Approved in 26 countries in Europe and 33 in RoW.
- ✓ Launched in 40 countries.

Orvatez® €6.6m

Okedi® €5.4m

- ✓ Lead candidate Risperidone ISM®, a LAI of risperidone for schizophrenia.
- ✓ Launched in Europe in 2022 and approved in the U.S., Canada and Australia in 2024.

* LMWH (Bemiparin and Enoxaparin biosimilar) + other heparins


CDMO⁽¹⁾ business €Mn

Total €50.1m


⁽¹⁾ Contract Development and Manufacturing Organisation

To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 36-40) of the press release on the financial results for the first quarter of 2024. Said document is available on ROVI's website and may be accessed on the following link <https://www.rovi.es/en/shareholders-investors/financial-business-information>

Gross profit €Mn



SG&A expenses €Mn



R&D expenses €Mn €6.1

+17%


Product	Potential Indication	Current Situation	Key Milestones
Okedi® Risperidone, monthly	Schizophrenia	Approved	Approved in Europe and in the USA, Canada and Australia
Letrozole ISM®, annual	Breast Cancer	Clinical development on hold	Phase I: Superior oestrogen suppression vs Femara®
Letrozole LEBE, quarterly	Breast Cancer	Phase I	
Risperidone, quarterly	Schizophrenia	Phase I	

Concentrated on improving posology for already approved compounds, which benefits risk /reward profile


Multiple FDA /GMP approved facilities to support the platform

To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 36-40) of the press release on the financial results for the first quarter of 2024. Said document is available on ROVI's website and may be accessed on the following link <https://www.rovi.es/en/shareholders-investors/financial-business-information>

EBITDA €Mn



Net profit €Mn



(1) Calculated excluding R&D expenses in Q1 2024 and Q1 2023

News flow

SPECIALTY PHARMA

- ✓ Sales of enoxaparin biosimilar
- ✓ Additional new products to be launched
- ✓ Granting by the competent local authorities of the marketing authorisation of an Enoxaparin biosimilar outside Europe

CDMO

- ✓ Evolution of Moderna's vaccine manufacturing
- ✓ Announcement of new contracts

ISM® Technology Platform

- ✓ Launch of Okedi® in Europe, Canada and Australia (already launched in Germany, UK, Spain, Portugal, Italy, Austria, Greece and Serbia)
- ✓ Marketing of Risvan® in USA
- ✓ Phase I clinical development of a three-monthly formulation of letrozole (Letrozole LEBE)
- ✓ Phase I clinical development of Risperidone for a 3-monthly injection